J.P. Desager

1.3k total citations
68 papers, 1.1k citations indexed

About

J.P. Desager is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Pharmacology. According to data from OpenAlex, J.P. Desager has authored 68 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 14 papers in Endocrinology, Diabetes and Metabolism and 13 papers in Pharmacology. Recurrent topics in J.P. Desager's work include Analytical Methods in Pharmaceuticals (12 papers), Pharmacogenetics and Drug Metabolism (11 papers) and Analytical Chemistry and Chromatography (8 papers). J.P. Desager is often cited by papers focused on Analytical Methods in Pharmaceuticals (12 papers), Pharmacogenetics and Drug Metabolism (11 papers) and Analytical Chemistry and Chromatography (8 papers). J.P. Desager collaborates with scholars based in Belgium, United States and Luxembourg. J.P. Desager's co-authors include C. Harvengt, Yves Horsmans, Yves Horsmans, R. Hulhoven, Jacques Bélaïche, Édouard Louis, Olivier Dewit, U Gaspard, F. Heller and A.P. Geubel and has published in prestigious journals such as Journal of Chromatography A, Pharmacology & Therapeutics and Life Sciences.

In The Last Decade

J.P. Desager

67 papers receiving 962 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J.P. Desager Belgium 18 252 189 173 162 139 68 1.1k
E Hvidberg Denmark 19 139 0.6× 236 1.2× 143 0.8× 56 0.3× 407 2.9× 68 1.4k
Anthony M. Yurchak United States 15 99 0.4× 53 0.3× 243 1.4× 119 0.7× 63 0.5× 19 1.1k
P. D. Niedmann Germany 19 116 0.5× 263 1.4× 68 0.4× 107 0.7× 59 0.4× 40 1.8k
Franciszek K. Główka Poland 22 171 0.7× 146 0.8× 119 0.7× 244 1.5× 53 0.4× 106 1.5k
Eugene J. Segre United States 19 132 0.5× 75 0.4× 228 1.3× 147 0.9× 76 0.5× 41 1.2k
Robert I. Misbin United States 20 116 0.5× 258 1.4× 49 0.3× 415 2.6× 140 1.0× 53 1.3k
J H Eckfeldt United States 25 303 1.2× 352 1.9× 93 0.5× 570 3.5× 243 1.7× 59 2.6k
Rashmi Patwardhan United States 20 73 0.3× 103 0.5× 412 2.4× 71 0.4× 61 0.4× 35 1.2k
David H. Huffman United States 23 229 0.9× 75 0.4× 227 1.3× 85 0.5× 30 0.2× 41 1.4k
Shoichi Nakagawa Japan 18 100 0.4× 320 1.7× 109 0.6× 626 3.9× 145 1.0× 48 1.9k

Countries citing papers authored by J.P. Desager

Since Specialization
Citations

This map shows the geographic impact of J.P. Desager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.P. Desager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.P. Desager more than expected).

Fields of papers citing papers by J.P. Desager

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.P. Desager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.P. Desager. The network helps show where J.P. Desager may publish in the future.

Co-authorship network of co-authors of J.P. Desager

This figure shows the co-authorship network connecting the top 25 collaborators of J.P. Desager. A scholar is included among the top collaborators of J.P. Desager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.P. Desager. J.P. Desager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Horsmans, Yves, et al.. (2001). High 6-Thioguanine Nucleotide Levels and Low Thiopurine Methyltransferase Activity in Patients With Lupus Erythematosus Treated With Azathioprine. American Journal of Therapeutics. 8(3). 147–150. 13 indexed citations
2.
Bélaïche, Jacques, J.P. Desager, Yves Horsmans, & Édouard Louis. (2001). Therapeutic Drug Monitoring of Azathioprine and 6-Mercaptopurine Metabolites in Crohn Disease. Scandinavian Journal of Gastroenterology. 36(1). 71–76. 90 indexed citations
3.
Eeckhoudt, Stéphane, et al.. (2001). Midazolam and cortisol metabolism before and after CYP3A induction in humans. International Journal of Clinical Pharmacology and Therapeutics. 39(7). 293–299. 23 indexed citations
4.
Decaux, Guy, et al.. (2000). Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. Journal of Laboratory and Clinical Medicine. 135(3). 256–262. 44 indexed citations
5.
Stärkel, Peter, et al.. (1999). CYP 3A proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin. Life Sciences. 64(8). 643–653. 30 indexed citations
6.
Eeckhoudt, Stéphane, et al.. (1998). Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. Journal of Chromatography B. 710. 165–171. 18 indexed citations
7.
Horsmans, Yves, et al.. (1997). Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Alimentary Pharmacology & Therapeutics. 11(1). 165–170. 60 indexed citations
8.
Heller, F., Catherine Vandenplas, J.P. Desager, & C. Harvengt. (1993). The vitamin A fat-loading test in young normolipidemic subjects. Clinica Chimica Acta. 219(1-2). 167–176. 7 indexed citations
9.
Horsmans, Yves, J.P. Desager, R. Hulhoven, & C. Harvengt. (1993). Single‐Dose Pharmacokinetics of Cetirizine in Patients With Chronic Liver Disease. The Journal of Clinical Pharmacology. 33(10). 929–932. 24 indexed citations
10.
Desager, J.P., et al.. (1993). A pharmacokinetic evaluation of the second-generation H1-receptor antagonist cetirizine in very young children. Clinical Pharmacology & Therapeutics. 53(4). 431–435. 35 indexed citations
11.
Maele‐Fabry, G. Van, P. Therasse, J.P. Desager, et al.. (1993). Embryotoxicity of human sera from patients treated with isotretinoin. Toxicology in Vitro. 7(6). 809–815. 2 indexed citations
12.
Horsmans, Yves, J.P. Desager, & C. Harvengt. (1992). Absence of CYP3 A Genetic Polymorphism Assessed by Urinary Excretion of 6 β‐Hydroxycortisol in 102 Healthy Subjects on Rifampicin. Pharmacology & Toxicology. 71(4). 258–261. 34 indexed citations
13.
Hoof, R Van, J.P. Desager, C. Harvengt, et al.. (1992). Comparison of the Effect of Celiprolol and Nifedipine on Blood Pressure and Plasma Lipids. Journal of Cardiovascular Pharmacology. 20(2). 268–273. 9 indexed citations
14.
Desager, J.P., Yves Horsmans, & C. Harvengt. (1991). Lecithin: Cholesterol Acyltransferase Activity in Familial Hypercholesterolemia Treated with Simvastatin and Simvastatin Plus Low‐Dose Colestipol. The Journal of Clinical Pharmacology. 31(6). 537–542. 11 indexed citations
15.
Desager, J.P., et al.. (1989). Oral Bioavailability of Ampicillin and Amoxycillin Alone and Bound in Fixed Proportions to Sulbactam and Clavulanic Acid. Journal of International Medical Research. 17(6). 532–538. 4 indexed citations
16.
Desager, J.P., R. Hulhoven, C. Harvengt, et al.. (1988). Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic. Psychopharmacology. 96(1). 63–66. 17 indexed citations
17.
18.
Desager, J.P., et al.. (1987). Prevalence of drug hydroxylator phenotypes in Belgium. European Journal of Clinical Pharmacology. 33(4). 439–440. 8 indexed citations
19.
Desager, J.P., et al.. (1982). Effect of Hemodialysis on Plasma Kinetics of Fenofibrate in Chronic Renal Failure. ˜The œNephron journals/Nephron journals. 31(1). 51–54. 22 indexed citations
20.
Leonard, John P., J.P. Desager, Christian Beckers, & C. Harvengt. (1979). In vitro binding of various biological substances by two hypocholesterolaemic resins. Cholestyramine and colestipol.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 29(7). 979–81. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E Hvidberg Breakdown of academic impact, for papers by Anthony M. Yurchak Breakdown of academic impact, for papers by P. D. Niedmann Breakdown of academic impact, for papers by Franciszek K. Główka Breakdown of academic impact, for papers by Eugene J. Segre Breakdown of academic impact, for papers by Robert I. Misbin Breakdown of academic impact, for papers by J H Eckfeldt Breakdown of academic impact, for papers by Rashmi Patwardhan Breakdown of academic impact, for papers by David H. Huffman Breakdown of academic impact, for papers by Shoichi Nakagawa
Rankless by CCL
2026